Roles
- Associate Professor of Clinical Radiation Oncology
- Director of Billing and Compliance, Department of Radiation Oncology
- Interim Director, Dwoskin Proton Center
- Co-Chair, Sylvester Comprehensive Cancer Center PRMC (protocol monitoring and review committee)
- Member (scientist/researcher) Florida Prostate Cancer Advisory Council
-
Biography
Dr. Abramowitz is an Associate Professor in the Department of Radiation Oncology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He obtained a BA in biochemistry from Colgate University in 1998 where he was also a member of the men's rowing team and spent 6 months at NIH researching 3D protein structures using NMR (MRI). He worked as a Research Assistant at the University of Massachusetts School of Medicine in the Department of molecular Genetics and Microbiology while serving as the novice rowing coach for College of the Holy. He graduated with honors (AOA) from Temple University School in2003. He did a transitional internship at Crozier Chester Medical Center in Philadelphia and completed his residency in radiation oncology at Fox Chase cancer Center in Philadelphia serving as chief resident in 2007.
He was recruited to join the Department of Radiation Oncology at University of Miami in 2010 and currently serves as the Co-Chairperson for the genitourinary malignancies site disease group which oversees the clinical trial portfolio for prostate, bladder, kidney and testicular malignancies. He is also the Co-Chair of the protocol monitoring and review committee which oversees the scientific review of all clinical trials open at the cancer center. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
Dr. Abramowitz's research interests lie in the realm of applying novel technology to improve the efficacy of radiation treatment delivery predominantly to genitourinary, CNS and head neck malignancies. He is a lead investigator of international clinical trials and is a strong supporter of clinical research and access to clinical trials to improve outcomes for his patients through novel approaches. This now includes the utilization of proton therapy to the list of novel radiation tools available to accomplish these goals. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Clinical Trials
Viewing 0 of 6 clinical trials.
-
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
- Principal Investigator: Matthew Abramowitz
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Randomized Study of Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
- Principal Investigator: Matthew Abramowitz
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
- Principal Investigator: Matthew Abramowitz
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Not Accepting
-
Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel
- Principal Investigator: Matthew Abramowitz
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Not Accepting
-
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival (OS), Overall Duration of Response (O-DOR), local control and quality of life (QOL) for patients treated with DaRT.
- Principal Investigator: Matthew Abramowitz
- Study Phase: N/A
- Enrollment Status: Not Accepting
-
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Principal Investigator: Matthew Abramowitz
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
